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Introduction
In much the same way that genomic technologies are changing the complexion of
biomedical research, the issues they generate are changing the agenda of IRBs and research
ethics. Many of the biggest challenges facing traditional research ethics today — privacy
and confidentiality of research subjects; ownership, control, and sharing of research data;
return of results and incidental findings; the relevance of group interests and harms; the
scope of informed consent; and the relative importance of the therapeutic misconception —
have become important policy issues over the last 20 years because of the ways they have
been magnified by genomic research efforts. Research that examines the ethical, legal, and
social implications (ELSI) of human genomics research has become a burgeoning
international field of scholarship over the last 20 years, thanks in part to its support first by
the genome research funding bodies in the U.S. and then by national science agencies in
other countries. A large part of the intellectual effort in this field has been devoted to
identifying, highlighting, and analyzing critical issues in genomic research as it moves
through the translational process. Given the prominence of these issues in today’s debates
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over the state of research ethics overall, these studies are well positioned to contribute
important data, contextual considerations, and policy arguments to the wider research ethics
community’s deliberations, and ultimately to develop a research ethics that can help guide
biomedicine’s future.
In this essay, we illustrate this thesis through an analytic summary of the research presented
at the 2011 ELSI Congress, an international meeting of genomics and society researchers.
The Congress1 was supported by the National Human Genome Research Institute (NHGRI),
and hosted by the Center for Genomics and Society at the University of North Carolina at
Chapel Hill, one of six Centers of Excellence in ELSI Research.2 It was the third such
conference since the ELSI program was established in 1990.3 Featuring current and recent
ELSI research, the Congress provided a slice-of-time perspective through which to consider
a set of pivotal factors that characterize genomic research today, and that promise to increase
in significance as genomic research and practice continue to evolve.
ELSI Congress announcements to recruit paper and panel submissions were sent to multiple
national and international scholars, organizations, and institutions in the fall of 2010.
Themes were defined broadly. Applicants were asked to consider how ELSI research has
expanded since 2008, and how it has changed through links to other sciences and
disciplines, increased specialization, and internationalization. In October 2010, an
international planning committee4 was formed to review submissions and develop the
Congress agenda. Based on their particular expertise, committee members were assigned in
groups to conduct reviews, using criteria of relevance, clarity, significance, and originality.
A total of 35 Congress sessions were scheduled: 18 panels and 17 themed sessions,
comprising 79 papers overall. The Congress also featured invited plenary speakers and
workshops, but we focus here on the submitted research, as it offers a unique opportunity to
inductively assess the state of the field in ELSI research and to offer insights about research
ethics that are drawn from a wide variety of presentations.
Drawing on submitted abstracts, presentation slides, notes taken during each session by
volunteer rapporteurs,5 and the ELSI issues generated by advances in genomic research,6 we
identify three pivotal factors currently shaping genomic research, its clinical translation, and
its societal implications — each of which, in addition, represents contested concepts in
research ethics generally, and lessons for contemporary issues in research ethics. These
factors are: (1) the increasingly blurred boundary between research and treatment; (2)
uncertainty — that is, the indefinite, indeterminate, and incomplete nature of much genomic
information and the challenges that arise from making meaning and use of it; and (3) the
role of negotiations between multiple scientific and non-scientific stakeholders in setting the
priorities for and direction of biomedical research, as it is increasingly conducted “in the
public square.” In our discussion, we refer to individual and panel presentations from the
Congress with letters and numbers corresponding to the listing in the Appendix, and the
names of first authors when individual presentations in a session are cited. Additional
information about Congress presentations is available upon request.
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(1) Blurring the Boundary between Research and Treatment
Both the Belmont Report and the Common Rule emphasize the importance of the distinction
between research and treatment. An essential requirement of informed consent to research
has always been that patients recruited into studies must understand that the researcher-
subject relationship and its attendant rights and responsibilities are fundamentally different
from the relationship between physician and patient. In fact, since 1982, much empirical
work has been devoted to assessing the danger that patient-subjects (not to mention other
stakeholders) might misunderstand this critical distinction; that is, that they might fall prey
to the “therapeutic misconception.”7 At the same time, a lively conceptual debate has
developed regarding the relationship between research and treatment, primarily but not
exclusively in the context of clinical trials.8 ELSI researchers have made significant
contributions to these literatures, beginning by questioning the term “gene therapy” as
applied to early-phase gene transfer research.9
It is noteworthy, then, that an impressive number of papers and panels in the Congress
focused on aspects of a powerful shift that seems to be accompanying the genomic
revolution and concomitant attempts to move research toward personalized medicine as
quickly as possible. The issue of providing to research participants individual “results”
related to the aims of a study, or even findings that were uncovered “incidentally,” has
become increasingly controversial, generating heated debates regarding the norms and the
justifications for relaxing the strict boundary between research and treatment.10 Far from
receding as an issue largely settled by better conceptual clarity about the goals of clinical
research, the work presented at the Congress demonstrated that the blurriness of the
boundary between research and treatment has only been increased by the advent of genomic
tools and methods, in several respects.
The debate over whether — and if so, which, when, and how — results and incidental
findings from gene-finding and other genomic research should be provided to individual
subjects has been a long-standing focus of attention for ELSI researchers. Importantly, the
question itself exemplifies the blurring of research and practice in two ways. First, the very
expectation that any data arising from a research project will have meaning and value for
individual research subjects arises from the belief that the research will have direct and
immediate clinical significance. Second, the failure to distinguish between “research results”
and “incidental findings” — a blurring that, although not ubiquitous, is far from uncommon
— compounds the problem.
Genomics researchers struggle with the issue of returning individual research results to
participants because, in many if not most cases, the results are of uncertain meaning or
significance and thus may lead to misunderstanding, confusion, and harm when participants
attempt to make clinical sense of them. Return of incidental findings poses similar but not
identical problems. The provision to an individual participant of data that pertain to him or
her but are not directly related to the objectives of the study may not raise uncertainty issues
when deemed important enough to return. Nonetheless, the expectation that some clinically
meaningful information will be identified in genomic research contributes to the blurring of
research and clinical care.
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(a) Returning Incidental Findings
For example, a panel session [A-4] previewed the 2011 revision of the National Cancer
Institute Best Practices for Biospecimen Resources, examining (a) appropriate handling of
diagnostic discrepancies and incidental findings discovered during pathology review of
biospecimens; (b) return of results to individual research subjects in biospecimen research;
and (c) disclosure of aggregate research findings. The return of diagnostic discrepancies and
incidental findings with potential clinical significance most obviously blur the research-
treatment boundary, in the same way that this boundary is blurred in the context of other
research. Imaging studies, or for that matter screening or diagnostic studies in any clinical
trial, may uncover information of potential clinical importance that would not otherwise
have been found. The return of incidental findings in any research study thus raises
questions about the nature and scope of investigators’ duties of nonmaleficence and
beneficence to research subjects — questions that move research toward treatment by virtue
of the clinical significance of the findings at issue.
In a panel [D-1] that examined the ELSI implications for genomics of issues arising in
neuroscience, a paper by Judy Illes discussed the treatment of incidental findings in
neuroimaging and considered the similar issues arising from incidental findings in genomics
research. The familiar problem of incidental findings in clinical research more generally is
increased greatly in scope in biospecimen research, owing to its much greater magnitude and
scale. The collection of large numbers of biospecimens, and the technologies that permit
identification of multiple mutations potentially associated with common complex disorders
like cancer, make the identification of genetic variants that are not being looked for but that
may have clinical meaning far more likely. Thus there is both (1) a need to determine in
advance appropriate protocols for handling a high volume of incidental findings, and (2) an
expectation on the part of research subjects that information of potential clinical significance
is likely to be found.
Janet Williams and colleagues [E-6] documented this shifting terrain with research that
presented contrasting views held by IRB chairs compared to genomic researchers regarding
the return of incidental findings. While both groups agreed that the rapid development of
extensive genomic sequencing techniques is creating some urgency in addressing the issue,
they differed on whether research participants should be notified when an incidental finding
emerged. Researchers believed such notification goes beyond the scope of their
responsibilities, and thus there was little need to address incidental findings in consent
processes, but expected to look to IRBs for guidance when such findings appeared. In
contrast, IRB chairs believed that notification should be a concrete option, out of respect for
participants and acting in their best interests; that a wide range of information should be
included in consent forms; and that researchers had a duty to initiate the process of
responsible management of incidental findings.
Unless clinicians and researchers work hard to clarify the difference, returning individual
results may be viewed by potential subjects as essentially the same as handling incidental
findings, at least in part because the key question — What information obtained in research
has meaning for individual subjects? — is the same. The difference, of course, lies not in the
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question but in the answer, since the purpose of genomic research is precisely to gather
information whose meaning and value is yet to be determined.
(b) Returning Results
To classify any research results as worthy of returning to individual subjects requires the
establishment of criteria by which to assess their significance. Thus, criteria relevant to
answering the question include not only professional characterization of the findings (e.g.,
scientific validity or clinical utility), but also whether, and if so how, the possibility of
returning results to individuals is addressed in the research consent form — an inclusion that
may itself heighten public expectations about the direct clinical relevance of research results.
Importantly, NHGRI has recently funded research on these topics through several grant
mechanisms.11
Return of results has been examined in a wide range of studies of new genomic
technologies, such as whole genome sequencing, microarrays, and exome sequencing. These
new technologies have been utilized in conditions as diverse as breast cancer, Miller’s
syndrome, and coronary artery disease. A panel [G-1] examining these emerging analytical
technologies addressed patients’ and providers’ perceptions about the significance of
information derived from novel technologies for a range of research subjects: asymptomatic
individuals, families with extremely rare disorders, and individuals testing negative for well-
proven genetic associations.
Other Congress papers described variation in attitudes, practices, and assessments of this
boundary-blurring. Reed Pyeritz [E-6] addressed the “Duty to Recontact in the Genomics
Age,” outlining a broad spectrum of situations that might affect views about the criteria for
returning results and/or incidental findings, including: whether genetic variation is likely to
be pathogenic; whether a new gene is discovered that either causes or predisposes to a
condition for which evaluation was originally sought; whether potentially clinically
actionable information is to be returned to the research subjects; and whether abnormalities
that were outside the original indication for performing the study are identified. A survey of
attitudes and practices of GWAS investigators regarding return of individual results [E-6,
Ramoni] documented significant barriers, including uncertain clinical utility, the possibility
that participants might misunderstand the information, the potential for causing emotional
harm, and the need for access to a trained clinician. While two-thirds of the investigators
surveyed believed the return of individual results was justified under certain circumstances,
particularly to benefit participants’ health, the vast majority reported that they had no plans
to return results.
More specific contexts were also explored, providing evidence of complexity in assessing
the issue. For example, research on pharmacogenomics, which evaluates genetic variations
in an individual’s genome to predict how a patient may respond to a particular therapy or
dose, may involve fewer risks and more benefits (with likely high clinical utility) compared
to returning results from research on disease susceptibility studies [E-6, Dressler]. A very
different context for the debate on return of results was described by Laura Beskow [E-6], in
her work on ethical challenges in genotype-driven research recruitment. This type of
research design is a powerful tool for understanding human genetic variation. However,
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opinions differ regarding whether and how to provide the genetic findings that prompted
recruitment of an individual participant. Researchers and IRBs must consider the potential
harms of not disclosing to an individual the genetic variation that has prompted their
recruitment into a genotype-driven study, and compare these with the potential harms that
arise from offering to disclose information about the individual subject’s genetic make-up
that is of uncertain significance and, often, ultimately meaningless.
(c) Biobanking and Blurring
ELSI research examining biobanking also often highlights the issue of research-treatment
blurring. On the one hand, many biospecimen contributors are expected to donate without
anticipation of individual benefits, thus exemplifying “genetic citizenship.” Some biobanks
created from newborn blood spots, or as a result of collection and storage of biospecimens
and associated data from hospital inpatients, or even national biobanks, may espouse this
perspective. In contrast, other biobanks, including some of those maintained by disease
advocacy organizations, are created specifically for the benefit of contributors, with the
return of individual results as one goal [D-4, Thiel].
Pediatric biobanking complicates this picture in interesting ways. In one panel [E-2], Ellen
Clayton argued that pediatric biobanks are “Not Just Biobanks for Little Adults” — indeed,
that the return of results for children raises unique implications that have not been
extensively discussed. In the same panel, Holly Tabor used several examples from whole
exome sequencing studies to illustrate the challenges that arise in biobanking research with
biospecimens from children, including: the right not to know; results that may be clinically
actionable for family members but not necessarily for the child research subject; and the
dynamic nature of the meaning of genetic information over time. A second panel that
addressed pediatric biobanking included a paper on “The Gene Partnership: Implementing
the Informed Cohort in a Pediatric Setting” [B-4, Clinton], which described an innovative
way to include parents and children in ongoing consent and engagement of families: in
partnership they decide (1) how much information they would like to share about a
particular topic and (2) what information they would like to receive from the Gene
Partnership.
Thus, many presentations in the Congress helped to demonstrate a lively ongoing theoretical
discussion of the nature and scope of researcher obligations and benefit-sharing in genomic
research [A-2; A-5, Caga-Anan; A-5, Lehmann]. Findings presented at the ELSI Congress
play an important role in animating this theoretical discourse, and document perceptions that
the boundary between research and clinical care is increasingly blurred in the context of
translational genomic research [A-5, Whitener; A-8, McDonald; D-5, Cappella; G-5, Frank].
It is noteworthy that the scientific complexity of genomic research and the high degree of
public interest it attracts has highlighted the need to increase scientific literacy by means of
public education. Despite the recognition of this need, the blurriness of the research-
treatment distinction itself, as perceived by many genomic research subjects and potential
subjects, represents the primary challenge to efforts aimed at improving public
understanding of and dialogue about genomic research [B-3; E-1].
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In contrast, making aggregate results of genomic research available poses few blurring
problems, and may help to educate the public at large by virtue of educating increasing
numbers of biospecimen-providing research subjects. Thus, if biospecimen resources
undertake conscientious development of websitebased documents and plain language
summaries, return of aggregate results may contribute to public education about the limits of
genomic knowledge [A-4]. Similarly, direct-to-consumer genetic testing, which is focused
not on research but on return of individual test results, may itself be used as an additional
type of educational tool, as outlined by another Congress panel [D-2].
In sum, current ELSI research suggests that, despite a history of work in research ethics
attempting to clarify distinctions between research and treatment, problems fueled by the
uncertain boundaries of these concepts will continue to haunt biomedical research. These
conceptual uncertainties will be compounded by the scientific and clinical uncertainties of
much of the information that genomic research could propel across this boundary. These
uncertainties constituted the second major recurrent theme at the ELSI Congress, and seem
certain to animate research ethics debates even more widely in the future.
(2) The Varieties of Uncertainty
Uncertainty arises in the course of making meaning and use of information from genomic
research. As genomics illustrates, biomedical research is increasingly making massive
amounts of data about individual patients and research participants readily available long
before the clinical significance of that information can be established. Presentations at the
Congress [e.g., D-3] provided a wealth of insights about the impact of genomic information,
good ways to provide that information, counsel people about its meaning, and educate
clinicians and the general public about its limits, given a high degree of uncertainty. What is
learned from ELSI research can inform a reflexive, iterative developmental process,
whereby research moves from description to prescription and back again, in response to
what has been learned about how patients and the public understand and use genomic
information.
(a) Clinical Uncertainty
It was the rare presentation in the Congress that did not mention uncertainty as a critical
feature of the understanding and use of genomic information in all contexts. A wide range of
genetic screening and testing services, especially direct-to-consumer genetic screening/
testing, attempts to make use of new information about genetic associations, variations,
susceptibilities, and the like as predictive information for prevention and other decision-
making purposes, seeking to translate data of uncertain meaning rapidly into practice. The
ambiguities of understanding surrounding research into novel genomic technologies like
exome and whole genome sequencing and high-resolution microarrays [G-1] exemplify this
problem. A panel addressing non-invasive prenatal genetic testing [G-3] likewise considered
the ways in which ease of implementation of a new technology can lead to unconsidered,
even unfettered use without regard to genuine usefulness — in this instance, uncertainty
about how this more readily available but still ambiguous information should be used in
decisions about pregnancy and birth.
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A paper describing the detection of copy number variants in autism spectrum disorder noted
that the genetic test at issue, array comparative genomic hybridization, was quickly
becoming routine in clinical practice, even though the lack of diagnostic certainty arising
from test results caused many insurance providers to label the test investigational [B-7,
Shutske]. Similar challenges arise with prenatal microarray testing, which is newly available
clinically and has recently been recommended by the American College of Obstetricians and
Gynecologists for use in prenatal diagnosis when abnormal anatomic findings on prenatal
imaging are accompanied by a normal karyotype. Perhaps unsurprisingly, microarray testing
itself often provides uncertain results [E-7, Bernhardt]. Uncertainty also played a significant
role in papers addressing how cancer genetic risk assessment and cancer pharmacogenomics
are viewed by stakeholders outside academic medical centers, for whom advanced
diagnostics are newly accessible [D-7].
The translation of recently discovered genetic information into clinical care was addressed
by a panel [E-4] presenting the results of a project examining the implications of identifying
mutations associated with Long QT syndrome, a cause of sudden unexpected cardiac death.
Family decision-making has particular significance in Long QT syndrome, especially
regarding questions of whether and how to involve potentially affected adolescents or young
adults who may be particularly distressed by uncertainty of information about at-risk status
and risk-reducing interventions.
Other examples focused on adaptation to uncertainty. One paper [A-7, Biesecker] described
the development and use of an adaptation scale assessing how individuals affected by and at
risk of being affected by a genetic condition understand and come to terms with health
threats. Several panel sessions reported on survey and interview studies of patients’ and
families’ interpretation and use of genomic screening and testing results. One panel [B-1]
presented empirical evidence to inform practice and policy in personal genomics based on
responses to risk information. Such information includes, in the case of the REVEAL Study,
return of results from APOE testing, which signals risk for the development of Alzheimer’s
disease.
It is noteworthy that few observations about uncertainty in genetic screening and testing are
unique to genomic research or practice. One exception may be found in the possibility that
expansion of newborn screening may identify maternal disease [B-7, Buchbinder]. However,
genomics often simply makes more ambiguous information more readily available, thus
highlighting the need for expert professional understanding and the professional time and
talent to undertake the necessary education and counseling for patients and families. For
example, variants of unknown significance (VUS) have long presented very similar
challenges when they are identified in imaging studies. Today, VUS are frequently seen in
microarray testing, even when it is employed in the hope of making a more definitive
identification of as-yet-unexplained anomalies [B-7, Reiff; E-7, Bernhardt]. Another type of
VUS that is unique to genomics is copy number variants (CNVs), which are now detected
with some frequency in patients with autism spectrum disorder through array comparative
genomic hybridization [B-7, Shutske]. While, as noted above, this is becoming routine in
clinical care, newly identified CNVs do not provide definitive confirmation of etiology; this
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therefore may simply compound the uncertainty that parents already feel about the potential
severity and management challenges facing their children with autism spectrum disorder.
Another important arena of uncertainty is the longstanding controversy over whether
children should be tested to determine whether they are at genetic risk for adult-onset
disease. Even when the identified risk is relatively high, as in BRCA1 and 2, the balancing
of harms and benefits arising from early identification of uncertain risk and the assignment
of meaning to probabilistic information is significant for families [E-7, Bradbury].
Uncertainty also arises in novel ways in expanded newborn screening. It is well-recognized
that the expansion of newborn screening has resulted in identification of some disorders for
which little or no effective treatment is available, and in other instances, early identification
of disorders for which the timing and severity of manifestation are uncertain — both of
which give rise to concerns about labeling and stigmatization.12 Newborn screening for
Krabbe disease appears to combine these two concerns, as it detects both a treatable, early-
onset version of the disorder, which fits the paradigmatic phenylketonuria model for
newborn screening, and also a late-onset form, which is not treatable and thus fits the
Huntington’s Disease paradigm for strongly discouraging early diagnosis [D-6, Dees].
Newborn screening for common complex disorders raises similar challenges with respect to
uncertainty, because of the multiple genetic contributions each common complex disorder
represents. Type 1 diabetes is such a disorder, one which is currently not preventable but
which presents considerable uncertainty with respect to its likelihood and severity when
identified via expanded newborn screening [D-6, Kerruish].
(b) Conceptual Uncertainty
As genomics research delves into the uniqueness of individual bodies in search of
individualized health interventions, it has also shed new light on old uncertainties about
humans as individual bodies and about diseases as problems of those individual bodies. The
discovery of the human microbiome has called into question our very concepts of what it
means to be human by revealing the vast communities of microorganisms that not only live
in our bodies, but play an essential part in the functions of these bodies that we once thought
of as solely our own.13
In the case of research on the human microbiome, concerns about uncertainty have entered
at an early stage: in the very selection of research subjects. Because the Human Microbiome
Project has sought to sequence the microbiomes of “normal,” “healthy” subjects, researchers
have begun to question the very meanings of these terms, and the narrow range of potential
participants these criteria have yielded [A-3; G-5].
Genomic science has also brought us back, again and again, to long-standing debates about
the nature of illness — questioning how much of an individual’s risk of developing diseases
lies with the family, the community, and the society, and thus weighing interventions
focused solely on the individual against interventions that include or primarily target social
factors. Newborn screening debates bring these questions to the fore, as genetic risk factors
discovered in screening an individual infant may point to risk factors for the parents or other
family members [B-7]. The search for genetic factors in addictions has also highlighted the
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problems of solely individualistic conceptions of disease. Recent examination of media
representations of addiction has revealed a dichotomy between genetic determinism, on the
one hand, and simple “willpower” on the other [G-5]. Yet, despite the proven success of
social interventions such as indoor smoking bans and restrictions on tobacco sales, the role
of social factors has been largely ignored in public, media, and policy discourses, which
focus mainly on individual genetic susceptibilities and individual pharmaceutical
interventions.
Finally, genomics has brought new clarity to our understanding of racial groupings, but has
also intensified persistent uncertainties about the use of race as a category in research and
clinical care.14 One ELSI Congress panel highlighted several facets of race as a contested
category in biomedicine [A-8]. While self-reported race may be a useful point of entry for
clinicians seeking genetically targeted interventions for their patients, the social category
“race” does not necessarily capture the genomic complexity of populations and ancestry
groups. In fact, as one paper argued, there is a well-documented tendency to turn to racial
categories as proxies for population risk in the context of clinical uncertainty [A-8,
Cunningham].15 Current patenting regulations tend to reify “race” as a genetic category in
the development, testing, and marketing of new pharmaceuticals, a trend that has serious
implications for the design of clinical trials and the marketing of new drugs [A-8, Kahn].
This conflation of race with genetic ancestry is exacerbated by NIH policies on the inclusion
of underrepresented minorities in research, since these minority groups are defined by self-
reported race and ethnicity, rather than genetically defined ancestry groups [B-6].
Many genetic association studies use ancestry estimation in order to identify genetic
contributions to disease while mitigating the confounding effects of social stratification by
race or ethnicity. Yet this practice may bring up new uncertainties for communities whose
social identities depend upon an understanding of shared ancestry that may be challenged by
genetic testing. Interdisciplinary perspectives on the use of genetic ancestry estimation in
research must balance concerns about the entrenchment of ideas about race as a biological
category with a commitment to addressing health disparities that are caused more by social
differences than genetic ones [B-6].
While they are brought into dramatic focus by the lens of human genome research,
conceptual uncertainties about how we should understand health, illness, individual human
identity, and the connections between these ideas and the human groups into which we sort
ourselves for social, political, and scientific reasons, are important challenges for all
biomedical research. They are important because they implicate the goals of the research
enterprise, its foundational assumptions, and its driving hypotheses. Moreover, the ELSI
research presented at the 2011 Congress suggests that they are not uncertainties that can be
resolved through science alone. Rather, as critical as they are to scientific priority-setting
and direction, they ultimately are uncertainties that can only be resolved socially, through
negotiation between the many different parties they implicate.
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(3) Negotiating Genomics in the Public Square16
A significant part of ELSI research has always been looking beyond the challenges that
genomic technology can raise for scientists and clinicians to the larger questions it raises for
the public. During the tool-building era of the Human Genome Project itself, most ELSI
research looked ahead to anticipate the effects that increased genomic information would
have on society at large, through studies of its implications for insurance, employment,
privacy, and the justice system, as well as its potential impact on cultural notions of personal
and group identity, and concepts of normality and health. While these studies set the stage
for important policy developments like the Genetic Information Non-Discrimination Act,
they were also criticized by some for looking too far downstream from genomics, as if the
design and conduct of genome research itself required no discussion by societal stakeholders
beyond the scientific community. Indeed, the “Genomes to Society” portion of the ELSI
research agenda is sometimes still portrayed as operating at a distance from genome research
itself, as referring to “broader” or “downstream” considerations “beyond” the lab or clinic,
with the lowered urgency that distance connotes.
In the years since the completion of the Human Genome Project, however, it has become
obvious that in order to realize any translational goals for genomic research, a variety of
public interests, perceptions, and voices must be engaged in conducting the science itself. In
order to acquire the population samples and data that large scale genomics requires, the
scientific community must leave the academic lab to negotiate with other social institutions
— hospitals, public health agencies, communities, governments — that bring quite different
agendas and interests to the table. As the scientific community has made its way across this
crowded public square, ELSI researchers have accompanied them, to try to understand those
agendas and interests, and what their implications might be for science policy.
As a result, it is noteworthy that, despite the linear metaphor of a “translational pipeline”
that is often used to explain the classification of ELSI research projects addressing “genome
research issues,” “clinical integration issues,” and “societal impact issues,” one recurrent
theme that cuts across contemporary ELSI research is increased attention to the ways in
which societal interests and concerns and clinical realities and goals loop back to affect the
design and conduct of genome research itself. The amount of research currently addressing
public concerns and social agendas in conducting large scale and translational genomic
research is itself a testament to the way in which placing societal issues at the downstream
or distal end of the translational pipeline for genome research has both the distance and
direction wrong. ELSI research today is not really captured by a heading like “Genomes to
Society”: in fact, much of it might be more accurately called “Society to Genomics,” or even
“Genomics Through Society” research, because it proceeds on the assumption that genome
research can only make progress by coming to terms with the many different stakeholders it
needs to enlist in its efforts.
Differences in what research subjects want and expect and what researchers are prepared to
provide, as well as in what patients and the public want and what clinical genetic testing is
able to provide, were frequently highlighted in Congress presentations. A broad spectrum of
scientists, clinicians, patients, families, policymakers, and the public at large are
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participating in ELSI research and helping to shape how genetic information is explained
and applied. Newborn screening represents one such area, as does personalized genomics in
general (in direct-to-consumer genetic testing and other forms). Critiques of the usefulness
and cost of data acquisition and the uncertainty of analysis reflect the input of the public
square, as do debates about what is considered useful and by whom. For instance, one panel
session involved Congress attendees in a dramatic reading addressing different perspectives
on enrollment in gene-finding research within a family affected by a genetic disorder [E-3].
Research reports that illustrate this cross-cutting theme at the ELSI Congress can be
clustered into four overlapping sets of social/scientific negotiations, each focusing on a
different aspect of translational genomic research: its orienting goals, its driving hypotheses,
its methods for acquiring human genetic material, and the rules governing its transactions
with the human sources of that material. This is not surprising, since each of these features is
critical to the progress of the research, and each involves important normative choices: that
is, value judgments about what directions the research should take and how it should
proceed. In the case of translational genomic research, however, the questions raised by each
of these four features are particularly vexing.
(a) Negotiating Genomics’ Orienting Goals
In the promotional rhetoric of the scientific community, the success of much translational
genomics research is measured in terms of how fast and well it can realize the orienting goal
of personalized genomic medicine (PGM)17 in health care. But as ELSI researchers point
out, adopting PGM as the orienting goal for translational genomic research is not a value-
neutral choice: it puts our money on the virtues of this model for health care instead of
alternatives [A-2; D-2]. For biomedical research planners and their public funders,
embracing this goal responsibly means reconciling any health care trade-offs involved.
One way this challenge was illuminated at the ELSI Congress was by explorations of benefit
sharing and the reduction of health disparities as goals of translational genomic research
[A-1; A-2; B-6, Courtwright]. Genomics research now takes place in an era when the
potential beneficiaries of biomedical research have unprecedented knowledge of and
advocacy regarding research agendas and the translation of findings into health benefits.
Proponents of integrating stakeholders at every stage of the translational pathway argue that
translation is less a linear than a cyclical process, and that integrating the assessments of
multiple stakeholders into initial research design not only facilitates more democratic or
“just” translation, but produces better science from the outset [A-1]. Another angle on these
tensions was explored by several presenters for a panel examining the nature and limits of
researcher obligations to participants [A-5, Caga-anan; A-5, Lehmann; A-5, Marsden]. In
many instances, perhaps best exemplified by the return of results controversy [A-4],
consensus conferences and similar efforts demonstrate the attempt to incorporate the views
of stakeholder groups; without good empirical data, however, the value of consensus
documents can remain an open question.
For clinicians, health care institutions, and research participants, defining the goals of
translational genomic research also means ensuring that such research can yield meaningful
health benefits in practical contexts. This again involves taking seriously the perspectives of
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the different stakeholders who are involved in the health care system and are presumed to
benefit from outcomes of the research. Examples at the Congress include surveys and
interviews uncovering: differences between clinicians and insurance providers regarding
whether genetic testing should be regarded as standard or investigational [B-7, Shutske];
differences between genetic counselors’ evolving understanding of risk and the perceptions
of their clients [B-7, Stern]; the range of health conditions for which the general public
would seek genetic testing [B-7, Biesecker]; differences across jurisdictions and across the
citizenry in views about newborn screening, including conditions tested for and views about
consent [D-6, Grob]; views of the acceptability of newly available cancer genetic risk
assessment technologies among hospital administrators, clinicians, and at-risk individuals
[D-7, Miesfeldt]; and adoption of cancer pharmacogenomic testing among oncologists [D-7,
Dressler]. The introduction of novel genomic technologies like non-invasive prenatal testing
[G-3], exome sequencing, whole genome sequencing, and microarrays [G-1] similarly
demonstrates a diversity of perspectives between generalist and specialist clinicians,
scientists, patients, advocacy groups, and insurers.
(b) Negotiating the Driving Hypotheses of Translational Genomic Research
Proponents of genomic medicine assume that the best way to improve health care is to
understand human genomic variation and the regulation of human gene expression at as high
a level of resolution as possible. Translational genomic research priorities are set in terms of
these assumptions. But depending on the assumptions they make and the questions they
address, studies of the relevance of human genomic variation and gene expression to human
health can implicate the social, political, and economic interests of many stakeholders, from
individuals and families to communities and populations. For both genome scientists and
these other stakeholders, these competing interests raise normative questions about who
should be involved in the framing of particular translational genomic research hypotheses
and how genomic research results should be publicly interpreted, commercially developed,
and clinically applied, if we are to avoid disadvantaging those the research is intended to
help.
Genomic research has encountered and intensified social and political uncertainties for some
minority groups that are underrepresented in biomedical research. Addressing this challenge
was repeatedly marked as urgent by presenters because of the scientific, conceptual, and
political uncertainties that can get eclipsed in the process of moving too quickly from one
sphere to the next. One ELSI Congress panel detailed the creation of an international
Indigenous Genomics Alliance (IGA), which facilitates connections between indigenous
groups worldwide and the development of research frameworks that respect indigenous
values and self-determination [G-4]. Organizations like the IGA serve an important function
in the wake of past misunderstandings and exploitations of indigenous groups by genomics
researchers, and echo a wider call for community partnerships in genomics research that can
facilitate mutually beneficial research relationships.
While the Latino community has historically been poorly represented in biomedical
research, recent projects designed to increase Latino participation in research on autism
spectrum disorders have built community partnerships through trusted community-based
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organizations [B-3]. Ethical and social issues must be carefully addressed in using
community members and organizations as gatekeepers who assist researchers in accessing
potential research participants, but this exploratory research suggested that this model could
be implemented at other sites to help achieve more balanced representation of Latinos in
genetic research. Similarly, another ELSI Congress panel discussed the development of
community partnerships with marginalized and indigenous communities in the U.S. and
Peru, addressing community perceptions of genomics research and researchers and seeking a
better understanding of community needs that can lead to collaborative research
relationships [E-1].
In this respect, assumptions about what should count as legitimate risks for genome research
also come up in deciding how to frame the genomic research agenda. Should genomics be
concerned with social and cultural beliefs that might be challenged by scientific findings, or
let the “chips fall where they may” in terms of the social sequelae of genomic variation
research for group identity claims, values, and social coherence? Here, examinations of the
risks to cultural beliefs constitutive of our social fabric were discussed in the context of
microbiome research [G-5, Frank], ancestry studies [D-8, Ossorio], and population structure
and reputation [G-4].
(c) Negotiating Procurement Methods in Translational Genomic Research
Translational genomic research capable of illuminating genomic variation and gene
expression in ways that can lead to health benefits is only possible if researchers have access
to the raw materials they need: large numbers of DNA samples from genetically diverse sets
of people with relevant phenotypic traits. The design of any specific translational genomic
research project is shaped by the need to procure these annotated samples. But procuring the
raw materials for translational genomic research is not as straightforward as ordering
chemical reagents from a scientific supply house. In order to acquire the volume and kinds
of human DNA samples they require, genome scientists must build or turn to existing
collections of stored tissue from human beings. For these scientists, the managers of these
collections, and the people from whom biospecimens are obtained, this need raises
normative questions about dispositional authority over samples, ownership of intellectual
property [B-5], the privacy of the information that biospecimens yield, and how best to share
the benefits of research among those involved.
As a result, ELSI researchers are devoting significant effort to empirical studies of attitudes
and experiences of different populations about being involved in large scale or translational
research, including African Americans [A-8, McDonald], Native Americans and other
indigenous peoples [G-4; D-8, Ossorio], Latino families [B-3], technological elites [D-4,
Thiel; D-5, Cappella], and persons with low socioeconomic status, from both the urban
north [E-1] and the rural south [D-4, Mitchell]. Research on biobanking presented at the
ELSI Congress addressed community and public perceptions of biobanking and related
research, revealing the complexities of relationships between biospecimen providers and
researchers and the challenges these raise [B-4; D-4; E-2].
Nowhere are these ethical and practical questions more contentious than in pediatric
biobanking. Research on the policies and practices of organizations banking pediatric
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samples has revealed a wide range of decisions about the return of research results and
incidental findings, study withdrawal, consent/assent, and re-consent of minors when they
reach adulthood [B-4]. Pediatric biobanks must consider the unique features of consent in
the pediatric context, and address the amount of influence parents should exert to encourage
children’s participation. The disclosure of information during consent and of results
discovered during research also present challenges, especially because such information may
have equal or even greater implications for parents and other genetic relatives than for the
pediatric donor [E-2]. Equally thorny issues arise in the context of banking umbilical cord
blood and residual newborn screening samples for future research, since both of these types
of samples are collected immediately after childbirth, a context in which informed consent is
difficult at best [B-4]. As several panels discussed [B-4; D-4], recent legal battles in Texas
and Minnesota have highlighted the “gap between law and ethics” when newborn screening
samples are used for research without informed consent by parents. One panel reported that
efforts to engage the public on the issue of research using newborn screening samples have
resulted, on the one hand, in a recognition of the public’s desire for explicit requests for
consent when such samples are used for new research, and, on the other, in greater public
understanding and support of the value of such research [D-4].
(d) Negotiating Genomics’ Social Contract
Finally, translational genomic research takes place within a framework of moral norms,
professional codes, institutional procedures, and public policies that govern research with
human beings. This framework influences the ways in which human DNA samples can be
obtained and used in translational genomic research projects, potentially affecting their
ability to illuminate human genomic variation and expression. But abiding by the rules that
govern the approval and regulation of translational genomic research is not straightforward.
For the institutional committees that oversee this research and the scientists who design and
conduct it, the interpretation of our research ethics conventions, codes, and regulations poses
an array of specific normative questions about how best to proceed with research
recruitment, obtain informed consent, protect data confidentiality, and address the disclosure
and publication of results.
For example, one of the distinctive norms of basic genome research has been a commitment
to broad data sharing. Now that communities and advocacy groups exert influence alongside
funders and data producers as stakeholders in genomics research, new compromises and
guidelines are being considered with respect to data sharing [E-5]. Recent research has
shown that research participants and community members often approve of wide data
sharing for research purposes, but concerns remain regarding commercial use, retention of
donor/community choices about sharing and secondary uses, and potential loss of privacy
[D-5; E-5; G-2]. Loss of privacy is a particular danger for genomic data, which is potentially
identifiable given enough SNPs; and identifiability is especially problematic in the case of
rare genetic traits [B-5; D-5; G-2]. Researchers have voiced additional concerns about data
sharing, including the risks it poses to the assignment of credit for breakthrough discoveries,
which is crucial for career advancement and future funding through grants or patent revenue
[E-5]. On a broader scale, questions have emerged as to the feasibility, for current
hypothesis-driven research, of applying the rapid data-sharing principles that were designed
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to facilitate the generation of raw sequence data for the Human Genome Project [E-5]. This
model fits well with recommendations on genomic data sharing proposed by recent expert
groups, which advocate for longitudinal partnership with participants [G-2].
But if genomic data are to be shared, the governance of this “commons” must be decided.
ELSI Congress presentations reported on the NIH’s decision to restrict access to genomic
research data shared through dbGap, and on data governance policies that have altered
scientific practice in the U.S., in Mexico, and in the U.K. [B-5; E-5; G-2]. International
collaborations bring particular challenges, and one presenter elaborated on these challenges,
suggesting that some can be met through establishing shared values among members of
these consortia [E-5, Knoppers].
Another major topic of negotiation in the conduct of genomic research is how best to respect
the interests of communities when they are recruited to represent larger populations. Projects
were presented testing and proposing methods for building trust between the public and the
scientific community, by improving the dialogue between them about the risks, benefits, and
meaning of participating in translational research, such as Anderson’s study of methods for
promoting dialogue on the research uses of residual newborn screening bloodspots [B-4];
Whitener’s proposal for engaging American Indian communities in research through
community-based system development [A-5]; or West’s project on developing common
language for cross-cultural genetic research [A-5].
Similarly, panels at the ELSI Congress suggested various approaches to addressing the
issues raised by biobanking, the research it facilitates, and its public implications. One
presentation offered a multi-method approach to engaging parents in dialogue and policy-
making efforts on the use of residual newborn screening samples [B-4, Anderson]. Given the
challenges of informed consent in the biobanking context, where it is impossible to know all
possible future research uses for samples at the time they are donated, one paper suggested
an alternative model based on clinical advance directives, which bestow the ethical authority
for future decision-making on a surrogate [D-4, Solomon]. Another panel discussed
Vanderbilt University’s model of “human non-subjects research” using de-identified
samples from clinical treatment [E-2]. Under this model, risks are minimized through
governance, while patients are offered annual opportunities to opt out of future research.
Alternately, as described above, the “Informed Cohort” model provides a particularly
collaborative approach in which “personally controlled health records” facilitate
communication and the return of individual research results [B4, Clinton].
Finally, whether or not studies or sample storage are “large-scale” in the sense of drawing
on a large number of participants, the speed at which genomic science has advanced means
that genomic information is increasingly “large-scale” in its quantity, scope, and
implications. Several ELSI Congress panels addressed issues related to ownership, sharing,
and identifiability of genomic data. Although researchers regard samples and information as
valuable resources, their understanding of who owns these resources and what is entailed by
that ownership is often vague [B-5]. Researchers have also expressed concern that patenting
practices are creating “patent thickets” that inhibit the development of new genetic
diagnostic tools [B-5].
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By illuminating the ways in which all four critical elements of translational genomic
research — its goals, hypotheses, methods, and social constraints — are dependent on trade-
offs between scientific and non-scientific considerations, the 2011 ELSI Congress raises a
much broader question for research ethics. If biomedicine’s flagship research movement is
shot through with negotiations involving parties with different values and priorities, surely
the larger clinical research enterprise is subject to the same social forces. Should these forces
be embraced as the “democratization of science,” or resisted as the distortion of science by
social agendas? If such negotiations are inevitable and ubiquitous, how should they be
managed if they are to be dealt with responsibly?
Conclusion
Our review of presentations at the 2011 ELSI Congress identified three major, interrelated
themes for contemporary research ethics. First, new forces are reshaping the boundaries
between research and treatment, threatening to erase the dividing line initially set forth in the
Belmont Report. This challenge, which dates back to the early, problematic distinction
between “therapeutic” and “nontherapeutic” research,18 has long been recognized in
oncology research,19 and has more recently become pervasive. Contributing trends in
clinical research generally include the media’s role in promoting research results;20 the
increasing roles that patients and communities now often take in research design and
implementation; and communication of research results and incidental findings in studies of
all sorts. Whether these changes are ultimately appropriate and beneficial is as yet unclear.
Second, the unprecedented and often uncontrolled translation of genomic research into
commercial genetic testing and into clinical settings highlights ongoing controversy over the
nature and meaning of genomic information, for different populations, in different contexts.
Uncertainty has always been a key characteristic of scientific knowledge, but avoidance of
its implications is no longer so easy, now that large data sets and information-sharing have
become pervasive throughout clinical trials. As other areas of biomedical research
increasingly exploit the wealth of data made available by the new interoperability of
biobanks, databases, and electronic medical records, these issues of uncertainty promise to
become ubiquitous.
Third, ELSI research presented at the Congress drew attention to broader issues at play
whenever basic scientific research requires the participation of non-research institutions, the
private sector, and diverse communities in order to achieve its translational goals. Just as
genomics must juggle multiple agendas in crafting its large-scale translational projects,
biomedical research generally will increasingly face the ethical challenges involved in such
negotiations. The relationship between science and society has rarely before been the subject
of such comprehensive scrutiny.21
It is not a coincidence that the most prominent policy initiatives related to research ethics
today, such as the ongoing effort to revise the Common Rule22 and the recent research ethics
report by the Presidential Commission for the Study of Bioethical Issues,23 focus in no small
part on challenges that have been thrust into the limelight by human genome research. Issues
such as those raised by gene-hunting research with banked human tissue samples, by family
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studies involving potent informational risks, or by genomic variation studies of human
populations challenge our current views about the rights and interests of individual research
participants. As the tools and strategies of genome research spread across the biomedical
landscape, these challenges are becoming unavoidable. Fortunately, the ongoing work of the
ELSI research community can provide the larger research ethics community an important
head start on ensuring that its deliberations are well-informed and forward-looking.
Appendix
Presentation List from the “2011 ELSI Congress: Exploring the ELSI Universe”
A-1 Panel: Justice in Translation: Achieving Benefit for All from Genomic Science
Suzanne Holland, Helene Starks, S. Malia Fullerton, Wylie Burke
A-2 Panel: Research on the Genetics of Antisocial Behavior and Violence:
Implications for Social Control and Criminal Justice
Henry Greely, Megan Allyse, Paul Appelbaum, Nita Faraheny
A-3 Panel: A Next Generation of ELSI Research: The Human Microbiome Project
Pilar Ossorio, Amy McGuire, Richard Sharp, Cecil Lewis, Pamela Sankar
A-4 Panel: Ethical and Legal Implications of Return of Research Results to
Participants in Biospecimen Studies
Nicole Lockhart, Carol Weil, Rihab Yassin
A-5 Themed Papers: Community Issues
• Positive Obligations in Genetics/Genomics Research: Are There
Lessons to Be Learned from International Health Research Ethics?
E. Charlisse Caga-anan
• Partnering with Research Participants: What Researchers Owe
Participants
Lisa Lehmann
• Linking In: Patient Networks and Genetic Research
Wendy Marsden
• “Passed Down Through Our Blood”: Developing Common Language
for a Cross-Cultural Genetic Research Partnership
Kathleen West
• Engaging American Indian Communities in Research through
Community Based System Development
Ron Whitener
A-6 Themed Papers: The ELSI Enterprise
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• The Ethical Corporation?: Exploring the Ways the Private Sector
Engages ELSI
Jenny Dyck Brian
• Expanding ELSI- Challenges and Implications of Conducting ELSI
Research in the Critical Care Environment
Bradley Freeman
• ELSI Programs Across NIH: An Achievable Goal
Jennifer McCormick
• Mapping the ELSI Universe: Taking Stock of the Field
Clair Morrissey
• The “E” in “ELSI”
Rebecca Walker
A-7 Themed Papers: Public Rhetoric
• Development and Evaluation of an Adaptation scale: Use in Six Studies
on Living With or Being at Risk for a Genetic Condition
Barbara Biesecker
• Problem Solved?: Media Representations of iPS Cell Research
Timothy Caulfield
• Personalized Genomic Medicine and the Rhetoric of Patient
Empowerment: Implications for Research and Practice
Eric Juengst
• Framing Attitudes Toward Direct-to-Consumer Genetic Testing
Jocelyn Landau
• Geneticization of Race in the News Media
Jo C. Phelan
A-8 Themed Papers: Concept of Race
• “Clinical Uncertainty and the Use of Race as a Proxy for Genetics”
Brooke Cunningham
• Mandating Race: How the PTO is Forcing Race into Biotechnology
Patents
Jonathan Kahn
• Attitudes About Genetically Targeted Care Among African Americans
Jasmine A. McDonald
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• Race as a Genetic Category: Challenging Conventional Wisdom
John Moskop
B-1 Panel: Empirical Research to Inform Practice and Policy in Personal Genomics:
Lessons from the REVEAL Study, Multiplex Initiative, and Coriell Personalized
Medicine Collaborative
Robert Green, J. Scott Roberts, Colleen McBride, Eryn Gordon
B-2 Panel: The “Geneticization” of Food: ELSl lmplications of Genetically-
Modified Probiotics
Richard Sharp, Ruth Farrell, Patricia Marshall, Gail Geller
B-3 Panel: Ethical, Social, and Scientific Implications of Activities to Increase the
Representation of Latino Families in Bio-Medical/Genetics
Barbara Wheeler, Clara Lajonchere, Irene Martinez
B-4 Themed Papers: Pediatric Biobanking
• Methods for Promoting Public Dialogue on the Use of Residual NBS
Rebecca Anderson
• The Gene Partnership: Implementing the Informed Cohort in a
Pediatric Setting
Catherine Clinton
• Legal Regulation of Banking Newborn Blood Spots for Research:
What Can We Learn from State Approaches to Consent?
Katherine Drabiak-Syed
• Who’s Cutting the Cord? Social and Ethical Implications of Using
Publicly Banked Umbilical Cord Blood for Genetic Research
Aaron Goldenberg
• Evaluating the Landscape of Pediatric Biobanks
Danielle Soucier
B-5 Themed Papers: Ownership
• Examining University Researchers’ Views on Retention and
Ownership of Human Genetic Specimens
R. Jean Cadigan
• Intellectual Property Challenges for the Development of Novel
Genomic Diagnostics- An Emerging Picture
Subhashini Chandrasekharan
• An Investigation of Women’s Experiences of an IVF Egg Sharing
Scheme for Somatic Cell Nuclear Transfer Research.
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• Governing Data: A Study of Institutional Processes and Scientists’
Experiences with Genomic Data Sharing
Pilar Ossorio
B-6 Themed Papers: Race and Policy
• eMERGE-ing Complications: Race in the Era of Genomic Data Linked
to the EMR
Patrick Blackburn
• Trickle Down Breakthroughs: Can We Prevent Advances in
Translational Therapeutics from Worsening Health Disparities?
Andrew Courtwright
• Re-examining Inclusion in the Genome Era: Researchers’ Views of the
National Institutes of Health Policy and Guidelines on the Inclusion of
Women and Minorities as Subjects in Clinical Research.
Sarah Knerr
• What Are Our AIMs? Interdisciplinary Perspectives on the Use of
Ancestry Estimation in Genetics Epidemiology Research
Joon-Ho Yu
B-7 Themed Papers: Genetic Testing-Clinical Understanding
• Do People Distinguish Between Diseases When Offered Genetic
Testing for Multiple Common Health Conditions? Findings from an
Ancillary Study of the Multiplex Initiative
Barbara Biesecker
• Newborn Screening and Maternal Disease: A Case of Mistaken
(Patient) Identity
Mara Buchbinder
• Dealing with Uncertainty in Microarray Testing: Seeking
Understanding and the Need for Clarity
Marian Reiff
• aCGH Testing for Patients with Autism Spectrum Disorder: Is It
Research or Clinical Practice?
Krysta Shutske
• “Calculating Uncertainty: Genetic Counseling and the Development of
Genetic Risk in the United States”
Alexandra Stern
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D-1 Panel: “The Challenging Ethical, Legal, Policy, and Social Considerations in
Neuroscience Research: Intersections with Genetics”
Jennifer McCormick, Henry Greely, Judy Illes, Paul Appelbaum, Jonathan
Moreno
D-2 Panel: “Personal Genomic Testing as an Educational Tool: Legal Standards,
Ethical Questions, and Empirical Data”
Shawneequa Callier, Kelly Ormond, Reed Pyeritz, Richard Sharp
D-3 Panel: “Innovative Approaches to Qualitative Data”
Marsha Michie, Martha King, Rachel Haase, John Conley, Nancy Press
D-4 Themed Papers: Biobanking
• “Community Understanding of the MURDOCK Study”
Robert Mitchell
• “Mind the Gap: An Advance Directive/Surrogacy Model for the
Relationship Between Biobanks and Tissue Donors”
Stephanie Solomon
• “Town Hall and Online Responses to Informed Consent Models for
Public Health Biobanks”
Daniel Thiel
• “Reconsent in Genome-Scale Research: Implications for Engagement”
Susan Brown Trinidad
• “Biobanking Cancer Tissue: Patients Consider Excised (Tumour)
Tissue to Be ‘Connective Tissue’”
Eric Vermeulen
D-5 Themed Papers: Identifiability/Confidentiality
• Ethical Issues Regarding the Potential for Identifiability of Information
in a Public Genotype-Phenotype Database
Michelle Huckaby Lewis
• The Use and Understanding of Certificate of Confidentiality
Lauren Dame
• Non-Welfare Interests in the Uses of De-Identified Materials
Tom Tomlinson
• Public Opinion and Deliberation About Ethical Issues in Genetic
Testing: Comparing Qualitative, Quantitative and Elite Views
Joseph Cappella
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D-6 Themed Papers: Newborn Screening
• Ethical Paradigms of Genetic Screening
Richard Dees
• Citizens’ Values Regarding Expanded Newborn Screening and the
Role of Parental Consent: A Public Engagement Study
Yvonne Bombard
• Pausing for Reflection: Governance Challenges in the Age of “New”
Newborn Screening
Rachel Grob
• Parents’ Experiences of NBS for Type 1 Diabetes
Nikki Kerruish
• Notes from the Front Lines: Psychosocial Follow-up of Newborn
Screening
Joanna Fanos
D-7 Themed Papers: Genetic Testing- Modes of Delivery
• Delivery of Cancer Genetic Services: Acceptability of Models of Care
in a Geographically Remote Setting
Susan Miesfeldt
• Cancer Pharmacogenomic Testing, Clinician Adoption and Patient
Benefit
Lynn G. Dressler
• Gaps in Oversight of Nonmedical Genetic Testing
Sara Huston Katsanis
• Navigating a Research Partnership between Academics and Industry:
Collaborations with Personalized Genomic Testing Companies
Lisa Soleymani Lehmann
D-8 Themed Papers: Group Membership Concerns
• Does Specific Consent Cause People to Act Selfishly?: A Conjoint
Analysis of Privacy and Biobanks
Daryl Pullman
• Lessons From the Havasupai
Pilar Ossorio
• Impact of the Havasupai Lawsuit on Genetic Research Studies
Nanibaa’ Garrison
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• Genetic Testing in Immigration for Family Reunification: A
Comparison of US and Canadian Policies
Llida Barata
E-1 Panel: National and International Perspectives on Community-Based and
Community Engaged ELSI Research
Patricia Marshall, Cecil Lewis, Aaron Goldenberg, Nanibaa’ Garrison, Jodyn
Platt
E-2 Panel: Pediatric Biobanks: Not Just Biobanks for Little Adults
Ellen Clayton, Benjamin Wilfond, Holly Tabor, Kyle Brothers
E-3 Panel: Genes and Plays: Exploring New Approaches and New Perspectives
Karen Rothenberg, Lynn Bush
E-4 Panel: Ethical, Legal and Social Issues in Genetic Testing Following
Unexpected Deaths: Translation of Cardiogenetic Knowledge to Clinical
Practice
Siobhan Dolan, Marina Stolerman, David Wasserman
E-5 Themed Papers: Data-Sharing
• Stakeholder Views on Data Sharing Policies: Who Wins, Who Loses,
and Why?
Helene Starks
• Examining the History and Implications of the ‘Bermuda Principles’
for Data Sharing
Rachel Ankeny
• Bermuda’s Legacy: The Future of Pre-Publication Data Release in the
Post-Genome World
Jorge L. Contreras
• Complexity, Genomics and Science Regulation
Jesus Siqueiros
• International Governance for International Consortia?
Bartha Knoppers
E-6 Themed Papers: Return of Results
• Ethical Challenges in Genotype-Driven Research Recruitment
Laura Beskow
• Return of Individual Research Results from Pharmacogenomic Versus
Disease Susceptibility Studies
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• Duty to Recontact in the Genomic Age
Reed Pyeritz
• Attitudes and Practices of Genome Investigators Regarding Return of
Individual Genetic Test Results
Rachel Ramoni
• IRB Chair and Researcher Perspectives on the Emergence of Genomic
Incidental Findings
Janet Williams
E-7 Themed Papers: Pediatric Genetic Testing
• “It’s a Little Bit of a Black Box”; Patient and Provider Experiences
with the Uncertainties of Prenatal Microarray Testing
Barbara Bernhardt
• Considering the Genetic Testing of Minors for Adult-Onset Disease.
Parent Opinions and Experiences with Early Communication.
Angela R. Bradbury
• Informed Consent Process in Alpha-1 Testing of At-Risk Children:
Views of Parents and Adults Tested as Children
Marilyn Coors
• Assessment of Parental Attitudes About Genetics and Congenital
Hearing Loss
Cynthia Powell
• Diagnosis Down Syndrome: Parental Perceptions of the Informing
Process
Marcia Van Riper
G-1 Panel: Ethical Challenges and Sociocultural Dimensions of Emerging Genomic
Analyses: Data from Recent Studies of ExomelWGS
Holly Tabor, Barbara Bernhardt, Debra Skinner, Flavia Facio, Richard Sharp
G-2 Panel: Genomic Data Sharing: Perspectives on Building a Community Resource
in the US and Abroad
Amy McGuire, Naomi Hawkins, Jill Oliver, Susan Trinidad
G-3 Panel: Conceiving Future Generations: Ethical, Legal, and Social Issues
Surrounding Non-Invasive Prenatal Genetic Testing
Mildred Cho, Lauren Sayres, Mark Nunes, Susan Kelly, Jaime King
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G-4 Panel: Rebuilding Our Nations: Strategies of Indigenous People to Navigate the
Ethical, Legal and Social Landscape of Genomic Research
Rosalina James, Nanibaa’ Garrison, Maui Hudson, Maile Taualii, Ron Whitener
G-5 Themed Papers: Gene-Environment/Microbiome
• Media Representations of Gene-Environment Interaction in Addiction
Research: Implications for Substance-Use Policy
Molly Dingel
• Gene by Environment Interaction in the Context of Behavioral
Genetics: Public Understanding of Eating Disorder Causation
Michele Easter
• Human Microbiome Research and the Social Fabric
Lily Frank
• Imagining and Defining Who Will Be “Normal” Volunteers for Human
Microbiome Research
Sheryl McCurdy
• “Snake-Oil,” “Quack Medicine,” and “Industrially Cultured
Organisms.” Investigators’ Perspectives on the Commodification and
Commercialization of the Human Microbiome
Melody Slashinski
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